Saturday 17 October 2026
Export DRMA’s income statement to Excel — free account
Dermata Therapeutics, Inc.
DRMA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 55.4% and free cash flow grew 9.99%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.86
0.05
−5.49%
Follow DRMA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
4.79 | 1.79 | 4.91 | 7.53 | 7.66 | 0.16 | 1.20 | — |
Net Debt/EBITDA |
0.97 | 0.25 | 0.92 | 0.65 | 1.38 | (0.98) | 0.16 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 585.57% | 62.14% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.12) | (6.11) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.03 | 0.91 | 0.82 | 0.92 | 0.54 | 1.24 | 0.83 | — |
Capex/Depreciation |
— | — | — | — | 0.00 | 0.00 | 0.00 | — |
Interest Coverage |
— | — | 32.53 | 152.11 | (172.30) | (16.08) | (17.83) | — |
| (194.20%) | (310.44%) | (125.96%) | (119.18%) | 134.00% | 13.42% | 19.58% | — | |
| (132.63%) | (213.46%) | (104.46%) | (103.52%) | (171.14%) | (242.32%) | (457.10%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(121.45%) | (787.11%) | (122.65%) | (159.60%) | (103.54%) | 101.84% | (1,376.50%) | — |
Average Days of Receivables |
— | — | — | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Free Cash Flow per Share |
(8.38) | (72.96) | (328.66) | (1,920.48) | (3,163.00) | (5,035.62) | (4,902.87) | — |
Cash per Share |
8.12 | 20.66 | 381.44 | 1,356.80 | 5,999.33 | 663.00 | 2,489.75 | — |
Shareholders Equity per Share |
6.72 | 10.20 | 325.90 | 1,309.11 | 5,615.06 | (3,972.37) | (262.75) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
6.72 | 10.20 | 325.90 | 1,309.11 | 5,615.06 | (3,972.37) | (262.75) | — |
Free Cash Flow |
(7.76) | (11.16) | (6.41) | (8.83) | (5.69) | (4.03) | (3.92) | — |
Working Capital |
6.22 | 1.56 | 6.36 | 6.02 | 10.11 | (3.18) | 0.34 | — |
Net Current Asset Value |
6.22 | 1.56 | 6.36 | 6.02 | 10.11 | (3.18) | (0.21) | — |
| Other line items | ||||||||
Quick Ratio |
4.59 | 1.60 | 4.58 | 6.76 | 7.12 | 0.14 | 1.16 | — |
Depreciation/Fixed assets |
— | — | — | — | 0.00 | 0.00 | 477.00 | — |
Cash ROIC |
(56.44%) | (236.37%) | (46.46%) | (72.04%) | (27.23%) | (448.56%) | (127.96%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(8.38) | (72.96) | (328.66) | (1,920.48) | (3,163.00) | (5,035.62) | (4,902.87) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
0.63 | 0.84 | 0.68 | 0.51 | 0.31 | 0.22 | 0.22 | — |
Average Assets |
5.70 | 5.76 | 7.46 | 9.28 | 6.11 | 1.34 | 1.03 | — |
Average Common Equity |
3.89 | 3.96 | 6.19 | 8.06 | (7.81) | (24.11) | (24.11) | — |
Columns are period end dates